1 Departmento de Ciências Patológicas, Universidade Estadual de Londrina, Londrina, Paraná, Brasil; and.
2 Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Am J Respir Cell Mol Biol. 2019 Jan;60(1):28-40. doi: 10.1165/rcmb.2017-0289OC.
Although cellular senescence may be a protective mechanism in modulating proliferative capacity, fibroblast senescence is now recognized as a key pathogenic mechanism in idiopathic pulmonary fibrosis (IPF). In aged mice, abundance and persistence of apoptosis-resistant senescent fibroblasts play a central role in nonresolving lung fibrosis after bleomycin challenge. Therefore, we investigated whether quercetin can restore the susceptibility of senescent IPF fibroblasts to proapoptotic stimuli and mitigate bleomycin-induced pulmonary fibrosis in aged mice. Unlike senescent normal lung fibroblasts, IPF lung fibroblasts from patients with stable and rapidly progressing disease were highly resistant to Fas ligand (FasL)-induced and TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Senescent IPF fibroblasts exhibited decreased expression of FasL and TRAIL receptors and caveolin-1, as well as increased AKT activation, compared with senescent normal lung fibroblasts. Although quercetin alone was not proapoptotic, it abolished the resistance to FasL- or TRAIL-induced apoptosis in IPF fibroblasts. Mechanistically, quercetin upregulated FasL receptor and caveolin-1 expression and modulated AKT activation. In vivo quercetin reversed bleomycin-induced pulmonary fibrosis and attenuated lethality, weight loss, and the expression of pulmonary senescence markers p21 and p19-ARF and senescence-associated secretory phenotype in aged mice. Collectively, these data indicate that quercetin reverses the resistance to death ligand-induced apoptosis by promoting FasL receptor and caveolin-1 expression and inhibiting AKT activation, thus mitigating the progression of established pulmonary fibrosis in aged mice. Therefore, quercetin may be a viable therapeutic option for IPF and other age-related diseases that progress with the accumulation of senescent fibroblasts.
虽然细胞衰老可能是调节增殖能力的一种保护机制,但成纤维细胞衰老现在被认为是特发性肺纤维化 (IPF) 的一个关键发病机制。在老年小鼠中,凋亡抵抗性衰老成纤维细胞的丰度和持续存在在博来霉素刺激后非消退性肺纤维化中起着核心作用。因此,我们研究了槲皮素是否可以恢复衰老的 IPF 成纤维细胞对促凋亡刺激的敏感性,并减轻老年小鼠中博来霉素诱导的肺纤维化。与衰老的正常肺成纤维细胞不同,来自稳定和快速进展疾病的 IPF 肺成纤维细胞对 Fas 配体 (FasL) 和 TNF 相关凋亡诱导配体 (TRAIL) 诱导的凋亡具有高度抗性。与衰老的正常肺成纤维细胞相比,衰老的 IPF 成纤维细胞表现出 FasL 和 TRAIL 受体以及 caveolin-1 的表达降低,而 AKT 激活增加。虽然槲皮素本身没有促凋亡作用,但它消除了 IPF 成纤维细胞对 FasL 或 TRAIL 诱导的凋亡的抗性。从机制上讲,槲皮素上调 FasL 受体和 caveolin-1 的表达并调节 AKT 激活。体内,槲皮素逆转了博来霉素诱导的肺纤维化,减轻了老年小鼠的致死率、体重减轻以及肺衰老标志物 p21 和 p19-ARF 和衰老相关分泌表型的表达。总之,这些数据表明,槲皮素通过促进 FasL 受体和 caveolin-1 的表达和抑制 AKT 激活来逆转死亡配体诱导的凋亡的抗性,从而减轻老年小鼠中已建立的肺纤维化的进展。因此,槲皮素可能是 IPF 和其他随衰老成纤维细胞积累而进展的与年龄相关的疾病的可行治疗选择。